Ivermectin vs Mebendazole vs Fenbendazole for Cancer: The Complete Evidence Guide (2026)
OneDayMD Evidence Guide · Cancer & Repurposed Medicines
A one-stop review of the laboratory research, human clinical studies, patient stories, commonly discussed protocols, safety concerns and primary references for three antiparasitic medicines that have attracted attention as possible cancer treatments.
Updated: 13 October 2026 · Editorial review: OneDayMD Editorial Team · Scope: Evidence appraisal and source navigation, not an individualized treatment plan.
Sources: ASCO Clinical Notice (17 June 2026); American Cancer Society: What to Know About Ivermectin (21 May 2026).
On this page
- The bottom line
- Ivermectin vs mebendazole vs fenbendazole
- How to read the evidence
- Ivermectin and cancer
- Mebendazole and cancer
- Fenbendazole and cancer
- Combination protocols and the 2026 observational preprint
- Joe Tippens, William Makis and patient success stories
- Risks, interactions and warning signs
- How to assess and document a cancer case
- Clinical trials and research references
- OneDayMD archive and related pages
- Frequently asked questions
The bottom line: what does the evidence show?
All three medicines have been discussed in cancer research, but the evidence is very different for each. Experiments in cancer cell lines and animals can identify hypotheses; they cannot establish that a drug safely treats a person’s cancer. A patient story may be worth documenting, but it cannot by itself identify the cause of a remission or show that the same outcome is likely for another person.
- Ivermectin: Laboratory and animal studies report possible anticancer mechanisms. Human evidence is insufficient to establish benefit, and no major randomized trial has confirmed that ivermectin treats cancer.
- Mebendazole: It has the most developed human oncology research of the three, including early-phase studies and trials combined with chemotherapy. Results have been mixed or disappointing, and it is not an approved cancer treatment.
- Fenbendazole: Most anticancer claims rest on preclinical research and anecdotes. It is a veterinary drug without an established human oncology dose or adequately characterized long-term human safety profile. Published case reports document serious liver injury associated with self-administration.
- Combinations: Evidence for a multi-drug protocol cannot be inferred from evidence for any single ingredient. Combining drugs and supplements can introduce additional toxicities, interactions and uncertainty.
Editorial conclusion: These medicines remain investigational for cancer. The most useful next step is not to copy a dosage posted online; it is to distinguish a mechanistic hypothesis from human clinical evidence, verify the underlying records, and discuss any proposed intervention with a qualified oncology team.
Ivermectin vs mebendazole vs fenbendazole
| Medicine | Established human use | What cancer evidence exists? | Key limitation | Practical conclusion |
|---|---|---|---|---|
| Ivermectin | Certain parasitic infections and selected topical indications, depending on formulation and jurisdiction. | Preclinical cell and animal studies; reviews of potential mechanisms; case stories and an observational preprint about a combination product. | No robust clinical evidence establishing an anticancer benefit in people; high or unapproved dosing may be dangerous. | Not an established cancer treatment or evidence-based add-on outside a well-designed clinical trial. |
| Mebendazole | Treatment of selected worm infections in humans. | Preclinical studies, case reports, a phase 2a gastrointestinal cancer study and a randomized phase II recurrent-glioblastoma trial in combination with chemotherapy. | Early studies do not establish routine clinical efficacy; one GI study reported progression in all patients who reached the 8-week tumour evaluation. | A repurposing research candidate, not a proven substitute or routine adjunct for cancer treatment. |
| Fenbendazole | Veterinary antiparasitic; not approved by the US FDA for human use. | Laboratory and animal work, individual testimonials and published human liver-injury reports after self-administration. | No established human cancer dose, no robust human efficacy trials, and limited human pharmacokinetic and safety data. | Do not self-administer veterinary formulations for cancer; its anticancer value and safe human dose are unproven. |
Drug approval is indication-specific. Approval to treat a parasitic infection does not demonstrate effectiveness against cancer. Regulatory status differs by country; verify local prescribing information.
How to read the evidence: OneDayMD E0–E5 framework
To keep headlines, testimonials and clinical findings from being mixed together, this guide uses the following practical evidence labels. The labels summarize the type of evidence; they are not a formal replacement for a systematic review or a GRADE assessment.
| Label | Evidence type | What it can tell us | What it cannot establish alone |
|---|---|---|---|
| E0 | Mechanism or computational hypothesis | Suggests a pathway or target to investigate. | That the drug reaches the target safely in a patient or improves outcomes. |
| E1 | Cell culture / in vitro | Shows effects under specified laboratory conditions. | A safe, effective dose in humans; many laboratory concentrations are not clinically achievable. |
| E2 | Animal / in vivo preclinical model | Adds information about tumour biology, exposure and whole-organism effects. | Human benefit, because animal models do not reproduce every human cancer or treatment response. |
| E3 | Case report, case series or testimonial | A signal worth checking and documenting in context. | Causation, response rates, likely benefit, or safety for a wider population. |
| E4 | Prospective observational study or early-phase clinical study | Feasibility, preliminary safety, exposure and early outcome signals. | Efficacy without adequate controls, objective outcome assessment and attention to bias. |
| E5 | Robust comparative clinical evidence and independent replication | Can support treatment decisions when results are relevant to the cancer and patient. | Universal benefit across all cancers; outcomes remain cancer-, patient- and regimen-specific. |
For ivermectin and fenbendazole as cancer treatments, the available evidence does not establish E5-level clinical benefit. Mebendazole has reached early human oncology studies, but those studies have not established it as a standard cancer treatment. Cancer type, histology, stage, molecular profile, dose exposure, concurrent treatment and outcome definitions all matter.
Ivermectin for cancer: what is known?
Why it is being studied
Preclinical publications have investigated ivermectin in a range of laboratory cancer models. Proposed mechanisms include effects on cell signalling, cell-cycle regulation, mitochondrial function, apoptosis and tumour–immune interactions. Such findings may help researchers design future experiments, but a mechanism observed in a dish is not proof of a therapeutic effect in humans.
A 2025 review in Current Oncology summarized preclinical findings while emphasizing the limited human evidence and the absence of large randomized trials confirming anticancer benefit. Read the review: Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? (PubMed).
Is ivermectin approved for cancer?
No. Ivermectin is approved for specific parasitic conditions and some other defined indications, depending on the formulation and jurisdiction. It is not approved to prevent or treat cancer, and no clinical guideline recommends it as a cancer treatment. ASCO's June 2026 notice specifically warned against using ivermectin as either cancer treatment or an adjunct to established therapy outside a well-designed clinical trial.
Do cancer-cell studies establish a human dose?
No. A concentration that affects cancer cells in vitro cannot simply be converted into an oral dose for a patient. Absorption, metabolism, distribution into tumour tissue, drug interactions and toxicity all affect whether an exposure can be reached safely. Human ivermectin dosing studies for parasitic disease should not be cited as proof that high-dose regimens are safe or effective for cancer.
Evidence status: Mainly E1–E2 for direct anticancer effects; some E3 reports and E4 observational material exist, but the evidence does not demonstrate clinical efficacy. Do not use online cancer-dosing calculators or protocol tables as a treatment plan.
Mebendazole for cancer: the most developed human evidence of the three
Why researchers are interested
Mebendazole is a human antiparasitic medicine in the benzimidazole class. Laboratory and animal work has examined its effects on microtubules, cell division and other cancer-related pathways. Several studies have explored whether it could be repurposed for brain tumours, gastrointestinal cancers and other malignancies.
Phase 2a study in advanced gastrointestinal cancer
Mansoori and colleagues published a phase 2a study in Scientific Reports in 2021. Eleven patients were enrolled and ten entered the treatment phase. Two stopped before tumour evaluation; the remaining eight had CT assessment at eight weeks, and all eight had progressive disease. Only five patients reached the study's target serum mebendazole concentration. This small study does not rule out every possible formulation or combination, but it did not show a clinical response signal in that cohort.
Primary source: Mansoori et al., phase 2a study (PMID 33903692) · Full article / DOI.
Randomized phase II study in recurrent glioblastoma
A randomized, open-label phase II study tested mebendazole added to either lomustine or temozolomide in recurrent glioblastoma. Both groups received mebendazole with chemotherapy, so there was no chemotherapy-only control arm to isolate the effect of mebendazole. Nine-month overall survival was 36.6% in the temozolomide–mebendazole arm and 45.0% in the lomustine–mebendazole arm, below the study's pre-specified 55% benchmark for further evaluation. These findings do not establish an overall-survival benefit attributable to mebendazole.
Primary source: Mebendazole plus lomustine or temozolomide in recurrent glioblastoma: randomized open-label phase II trial (PMID 35747192).
What should readers conclude?
Mebendazole is a legitimate research candidate, and evidence from human trials should be discussed rather than ignored. But an established human antiparasitic indication does not automatically make prolonged high-dose use for cancer safe or effective. Trial protocols and doses are designed for monitored research and should not be copied from abstracts or blogs. Any future role would need to be shown in trials with appropriate outcomes, controls, cancer-specific eligibility criteria and safety monitoring.
Fenbendazole for cancer: laboratory signals, testimonials and a major safety gap
Preclinical research
Fenbendazole is a veterinary benzimidazole. Laboratory and animal research has explored possible effects on tubulin, cell division and cancer-cell metabolism. For example, a 2024 study in BMC Cancer investigated fenbendazole in ovarian-cancer cell models and animals. This supports further investigation in preclinical research; it does not establish treatment benefit in people.
Primary source: Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study (2024).
Is fenbendazole approved for people?
Fenbendazole is used in veterinary medicine and is not approved by the US FDA for human use. Its human pharmacokinetics, chronic safety, effective exposure and appropriate dose for any cancer remain inadequately established. Do not assume that a veterinary product is equivalent to a human medicine in formulation, quality control or safety.
Published liver-injury reports
Serious liver injury is not merely a theoretical concern. A 2021 report described severe liver injury in a patient with non-small-cell lung cancer who self-administered fenbendazole while receiving pembrolizumab; liver function improved after fenbendazole was stopped, and the report did not document tumour shrinkage. A 2024 report described histologically confirmed severe drug-induced liver injury associated with self-administration. Additional case reports have appeared since then.
- Drug-induced liver injury in a patient with non-small-cell lung cancer after self-administration of fenbendazole (2021).
- Severe drug-induced liver injury due to self-administration of veterinary fenbendazole (2024).
- Fenbendazole-associated liver injury during cancer immunotherapy: structured causality assessment (case report).
Evidence status: E1–E2 for anticancer effects; E3 for patient stories and safety case reports. Robust clinical evidence of anticancer benefit in humans is lacking. Given the safety gap, a self-directed veterinary-drug regimen is not a reasonable substitute for approved treatment or a monitored clinical trial.
Ivermectin plus mebendazole: what does the 2026 observational preprint show?
A 2026 document posted on Zenodo describes a prospective observational cohort of 197 cancer patients who were prescribed a compounded ivermectin–mebendazole product through a telemedicine program. The record reports that 122 people completed a follow-up survey at approximately six months and presents patient-reported outcomes, including regression, no current evidence of disease, stability and progression.
The study is still relevant as a source to examine critically, especially for understanding how real-world data are collected and what needs independent verification. Its headline percentages should not be presented as an expected response rate, a cure rate or proof that the combination works.
Also distinguish this cohort from a randomized clinical trial. An observational report can generate a hypothesis, but it cannot answer the same question as a trial comparing appropriately assigned treatment groups with pre-defined outcomes and independent safety monitoring.
Joe Tippens, William Makis and “success stories”: how should they be read?
The Joe Tippens story
The Joe Tippens story helped popularize fenbendazole for cancer after he described a favourable outcome while using a multi-component regimen. A personal account can explain why patients investigate a treatment, and it can be worth documenting. But it cannot establish what caused the outcome without verified medical records, a complete timeline, details of standard treatments and an appropriate comparison. A testimonial cannot tell readers how often the same outcome occurs, which patients might benefit or what the harms may be.
Dr William Makis and other high-dose protocols
Publicly discussed protocols attributed to Dr William Makis and other advocates combine ivermectin, fenbendazole or mebendazole with other drugs and supplements. These are not validated cancer regimens. Protocols promoted by an individual, even a clinician, are not equivalent to a treatment guideline or an adequately controlled trial. In 2026, OneDayMD's related ivermectin page also documented a public disagreement about high-dose protocol safety, including a warning attributed to Dr Paul Marik that the high-dose approach could be toxic and was not recommended by him. That disagreement reinforces why a blog should not present a universal high-dose protocol as established care.
For this reason, this evidence guide does not reproduce an actionable cancer dosage schedule or calculate patient-specific doses. No validated cancer dosing regimen has been established for ivermectin or fenbendazole, and the available mebendazole oncology dosing experience comes from monitored clinical studies rather than a proven self-treatment protocol.
What about the OneDayMD “760+ case reports” archive?
The archive is a collection of patient stories, social-media reports, case reports and other source material organized by cancer type. Treat it as a report collection, not a verified clinical registry or an efficacy study. A count of collected stories is not necessarily a count of unique, independently verified patients. Before calculating response percentages, the archive would need defined inclusion criteria, duplicate detection, source provenance, tumour type and stage, complete treatment timelines, independent confirmation of outcomes and follow-up for progression and adverse events.
Do not use “760+ success stories” as a synonym for 760 successful outcomes. The collection includes reports with different data quality, treatment combinations, standards of verification and clinical circumstances. Case reports can help identify questions for research; they cannot establish causality or reliable probabilities of benefit.
Safety, interactions and what patients should discuss with their oncologist
Ivermectin
- High or inappropriate doses can cause serious neurological toxicity, including seizures, coma and death.
- Gastrointestinal adverse effects may overlap with chemotherapy or other cancer-treatment toxicities.
- Drug interactions and effects on the overall treatment plan need a clinician's review.
Fenbendazole
- Human safety and pharmacokinetics are not adequately characterized for long-term or high-dose cancer use.
- Published cases describe serious liver injury, including in people receiving cancer immunotherapy, where drug-related liver injury may be difficult to distinguish from immune-related hepatitis.
- Veterinary formulations should not be treated as substitutes for approved human medicines.
Mebendazole
- Use for a human parasitic infection does not establish the safety of prolonged, high-dose oncology use.
- High-dose oncology protocols require medical supervision because liver abnormalities, blood-count effects and interactions may need monitoring.
- Do not infer that a dose used in an early-phase trial is a recommended dose for another cancer or for unsupervised use.
When to seek urgent medical help
Seek urgent assessment for jaundice, dark urine, severe or persistent vomiting, marked abdominal pain, unusual bleeding, confusion, severe drowsiness, new unsteadiness, seizures or a sudden deterioration in general condition. If a person has already taken a veterinary product or an unprescribed high dose, tell the treating team exactly what was taken, how much, when, and which other medicines or supplements were used. Do not wait for symptoms before disclosing it.
A practical discussion checklist
- Ask what standard treatments are recommended for the exact cancer subtype, stage and biomarker profile, and what the likely benefits and risks are.
- Show the oncology team the actual product label, ingredient list, dose, schedule and source—not just a screenshot of a protocol.
- Review interactions with chemotherapy, immunotherapy, targeted medicines, anticoagulants, anticonvulsants and supplements.
- Ask whether a registered clinical trial exists for the cancer type and whether using the proposed product could affect eligibility.
- Agree on objective outcome measures and safety monitoring before starting any clinician-directed investigational intervention.
Clinical trials and key references
Trial availability and recruiting status change. Use the linked registry record to check eligibility, sites, investigators, current status and whether results have been posted. A study listed on a registry is not proof that a medicine works; registration records the research plan.
1. ASCO Clinical Notice: ivermectin and fenbendazole
Published: 17 June 2026. ASCO encourages clinicians to ask patients about alternative therapies and warns against using ivermectin or fenbendazole as cancer treatment or adjunctive therapy outside a well-designed clinical trial.
2. American Cancer Society: What to Know About Ivermectin
Published: 21 May 2026. Patient-facing overview of unproven cancer claims, safety risks and how to evaluate treatment information.
3. Ivermectin cancer evidence review
Review: 2025. Summarizes in-vitro and animal studies while noting the gap in clinical evidence.
4. Mebendazole phase 2a study in advanced gastrointestinal cancer
Journal: Scientific Reports, 2021. A small study of individualized dosing; all patients who underwent the 8-week tumour evaluation had progressive disease, and target serum concentrations were not reached by all participants.
5. Mebendazole plus chemotherapy in recurrent glioblastoma
Study: Randomized, open-label phase II study published in 2022. Both groups received mebendazole with chemotherapy; the study did not meet its prespecified 9-month overall-survival benchmark.
6. Fenbendazole preclinical ovarian-cancer study
Journal: BMC Cancer, 2024. Laboratory and animal findings; not a human treatment trial.
7. Fenbendazole-related liver injury reports
Published case reports describe severe liver injury following self-administration of veterinary fenbendazole. These reports cannot estimate how often injury occurs, but they are important safety signals.
8. Ivermectin–mebendazole observational cohort preprint (2026)
Useful to inspect as an example of observational, patient-reported data; not proof of cause and effect. The Zenodo record identifies the document as a preprint.
9. ClinicalTrials.gov: mebendazole in colorectal cancer
Registry record for a study evaluating mebendazole as adjuvant therapy in colorectal cancer. Check the live record for current status and posted results before describing it as recruiting or ongoing.
Research search links: Search ClinicalTrials.gov for mebendazole and cancer · Search ClinicalTrials.gov for ivermectin and cancer · Search PubMed for fenbendazole and cancer.
OneDayMD archive: original pages and related reading
The following pages are preserved as source archives and topic-specific discussions. They should be read alongside the evidence assessment above, not as a set of endorsed treatment instructions. Update their introductions and calls to action so they point readers to this evidence guide and make the investigational status clear.
- Fenbendazole vs Mebendazole for Cancer: What Is the Difference? — drug comparison, benzimidazole background and links to research.
- Ivermectin, Fenbendazole and Mebendazole: Protocol Claims and References — retain as a critical review of the protocol paper and subsequent discussion; remove language implying proven safety, efficacy or a recommended regimen.
- Fenbendazole, Ivermectin and Mebendazole for Cancer: Case Reports and Patient Stories — archive of reports organized by cancer type; label outcomes by source and verification level.
- Ivermectin for Cancer: Dosing Claims and Safety Review — revise the headline and remove any calculator or dosing instructions that could be mistaken for a validated cancer regimen.
- Fenbendazole and the Joe Tippens Protocol — describe the story as a testimonial, not proof of efficacy; prominently link to the liver-injury case reports and ASCO notice.
- Dr William Makis Ivermectin Protocol: Evidence and Safety Review — clearly identify the proposed regimen as unvalidated and do not present high-dose combinations as standard care.
Frequently asked questions
Can ivermectin cure cancer?
No reliable clinical evidence establishes that ivermectin cures cancer or improves cancer outcomes. Laboratory findings and individual reports are not enough to demonstrate a treatment effect. Ivermectin is not approved for cancer, and ASCO advises against using it as treatment or an adjunct outside a well-designed clinical trial.
Is fenbendazole safer or better than mebendazole?
There is no sound human clinical evidence showing that fenbendazole is more effective or safer for cancer. Mebendazole has an established human antiparasitic use and has been studied in oncology trials; fenbendazole is a veterinary product with much less human safety information. Neither is an established cancer treatment.
Why do laboratory studies look promising if the drugs are not proven?
Cell and animal models can reveal biological activity, but human tumours, drug absorption, metabolism, achievable concentrations, immune effects and treatment interactions are much more complex. Many compounds that look promising before human trials fail to provide a meaningful clinical benefit.
Does a published case report prove that a drug worked?
No. A case report can describe an unusual outcome and generate a hypothesis, but it usually cannot isolate the effect of one drug from standard treatment, changes in disease biology, measurement variation or other factors. Multiple well-documented cases still need careful methods before response rates or causation can be inferred.
What does “no evidence of disease” (NED) mean?
NED usually means that tests performed at that time did not detect evidence of cancer. Its meaning depends on the cancer type, the tests used and the follow-up period. It does not, by itself, establish which treatment caused the result or guarantee that cancer will not recur.
Are the reported 760+ stories 760 confirmed cancer remissions?
No. The archive is a collection of reports, testimonials and other source material. Unless each entry is de-duplicated and independently verified with clinical records and follow-up, the total must not be represented as 760 confirmed patients or successful outcomes.
Is the 2026 ivermectin–mebendazole report a clinical trial?
The Zenodo record describes a prospective observational cohort and identifies the available document as a preprint. It does not have a randomized control group, and its follow-up outcomes were self-reported. It should not be described as a randomized trial or treated as proof that the combination caused the reported outcomes.
Should a person stop standard cancer treatment to try one of these medicines?
No. Do not stop, postpone or reduce prescribed surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy or other cancer treatment because of an online protocol. Ask the treating team about evidence-based options, clinical trials, symptom support and any potential interaction before taking a new medicine or supplement.
Final perspective
Interest in repurposed medicines is understandable: patients and families are looking for accessible options and better outcomes. The responsible response is to investigate claims rigorously, not to dismiss patient experiences automatically or promote them as proof. Ivermectin, mebendazole and fenbendazole provide distinct research questions, but the current evidence does not justify treating any of them as a proven cancer therapy. Stronger studies, transparent case documentation, independent outcome verification and careful safety monitoring are needed.
OneDayMD editorial standard: We aim to make health information freely accessible, separate evidence from speculation, identify uncertainty, and encourage decisions made with a qualified oncology team. This guide is for education and research navigation; it is not medical advice or a personalized treatment recommendation.
Editorial note: Trial records, approval status and source pages can change. Verify the current version of each linked source before publication or clinical decision-making.
.png)
.png)
Comments
Post a Comment